Advertisement

Topics

Companies Related to "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma" [Most Relevant Company Matches] - Page: 2 RSS

13:17 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma" found in our extensive corporate database of over 50,000 company records.

Showing "Lenalidomide Rituximab Maintenance Therapy Treating Patients With Cell" Companies 26–50 of 6,100+

Relevant

Amorcyte, Inc.

Amorcyte is a privately held biotechnology company developing cell therapy products to treat cardiovascular disease. Its lead product AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in AMI eve...


Opexa Therapeutics

Opexa Therapeutics is a commercialization driven biotechnology cellular therapy company that develops autologous personalized cell therapies for the treatment of various diseases. The Company is focused on its proprietary stem cell and T-cell technologies for the autologous use of peripheral blood derived adult stem cells in regenerative medicine as well as T cells for the treatment of autoimmune ...

Medistem Inc

Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia and congestive heart failure. Curr...


R-JAPAN Co., Ltd.

R-JAPAN Co., Ltd. is the advanced biotechnology company specialized in manufacturing mesenchymal stem cells regenerative therapy with stem cell technology of Biostar Stem cell Research Institute in Korea. R-Japan’s proprietary technology is to isolate, multiply, and store adult mesenchymal stem cells with ensuring genetic integrity. R-Japan currently ...

Hygieia, Inc.

Hygieia, Inc. is an emerging diabetes health care company developing new ways to improve the effectiveness of therapy while reducing the cost of diabetes care. Hygieia’s first product is a handheld Diabetes Insulin Guidance System (DIGS™) designed to improve insulin therapy effectiveness for patients. DIGS works in a way that makes it a feasible ...

U.S. Stem Cell, Inc.

U.S. Stem Cell, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell-based therapies that prevent or treat disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

TissueGene

Starting in 1997, the founders of TissueGene sought to uncover different surgical and gene-based therapeutics for a variety of arthritic conditions. The diligence soon paid off in the form of the first successful animal model for cartilage repair. Subsequently, in the middle of 1999, TissueGene, Inc was incorporated in the United States. TissueGene's initial findings resulted in the focused develo...

Sistemic Ltd.

Sistemic’s primary business is focused on providing innovative microRNA-based problem-solving services and kit-based products to areas of unmet need within Pharmaceutical, Biotechnology and the Cell Therapy research, development and manufacture markets. MicroRNAs are seen as the master controllers of a cell and as such Sistemic believe that they are p...

Triumvira Immunologics Inc.

Triumvira Immunologics, Inc. is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., a niche life-sciences investment bank, with the vision of developing novel T cell therapies that are safer and more efficacious than current cell therapy cancer treatments, including chimeric antigen receptor (C...

CDH Proton Center

CDH Proton Center, A ProCure Center, Warrenville, Ill., is one of a handful of facilities in the country that offer proton therapy, an advanced form of radiation to treat cancer. The four-room, 60,000 sq. ft. Center, opened Oct. 19, 2010, is the first for Illinois and has the capacity to treat up to 1,500 patients a year. The precision of proton therapy sp...

Vor Biopharma

Co-founded by PureTech Health (LSE: PRTC) and based on the pioneering work of Siddhartha Mukherjee, M.D., D.Phil, as well as Vor’s own intellectual property, Vor is developing a proprietary pipeline of best-in-class immunotherapies for patients. The Company is working with some of the world’s leading oncologists and immunologists including Hans-P...

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and wi...

Incara Pharmaceuticals

Incara Pharmaceuticals Corporation focuses on the protection and regeneration of tissue damaged by injury and disease. The company currently has programs in three areas: liver cell therapy and progenitor cell therapy as a treatment for liver failure; small molecule catalytic antioxidants as treatment for stroke and tissue damage; and deligioparin (formerly named OP2000), an ultra-low molecular wei...

GammaCan

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan’s initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan’s first product was entered to phase-II clinical trials.GammaCan’s innovative treatment...

Vineti, Inc.

Vineti is the first commercial, configurable cloud-based platform to expand patient access to life-saving cell and gene therapies. Vineti was co-founded by GE and the Mayo Clinic to solve the key challenges patients, medical providers, biopharmaceutical companies and regulators face in the delivery and commercialization of individualized therapies. The Vin...

Triumvira Immunologics, Inc.

Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current gene therapy cancer treatments, including chimeric antigen receptor (CAR) and engineered T ...

Methodist Rehabilitation Hospital

The 40-bed facility offers specialized care to patients recovering from strokes; brain and spinal cord injuries; multi-trauma, neurological disorders; cardiopulmonary procedures; and complex orthopedic surgeries such as amputations, hip fractures, and joint replacements. Amenities at the 48,000-square-foot facility include a therapeutic pool; therapy gym with the latest in rehabilitative equipment...

bluebird bio, Inc. bluebird bio to Present Updated Clinical Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti- BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASCO Annual Meeting

The Alliance for the Advancement of Adult Stem Cell Therapy and Research

The Alliance for the Advancement of Adult Stem Cell Therapy and Research, is a non-profit organization dedicated to promoting the use of adult stem cells in the research and treatment of life-altering diseases. This alliance also strives to ensure treatment for those who qualify and could not otherwise afford to receive it. To become a supporting member, p...

ECACC, Health Protection Agency

The European Collection of Cell Cultures (ECACC) was established in 1984 as a cell culture collection to service the research community and provide an International Depository Authority recognised patent depository for Europe. Over the last 20 years ECACC has expanded and diversified to become one of the premier collections of authenticated cell cultures in the world and this remains the core of E...

Xstrahl

Xstrahl is a leading designer and manufacturer of X-ray systems for use in cancer and dermatology treatments and radiation biology research, providing complete solutions for all X-ray therapy and research applications. Xstrahl has more than 15 years’ experience supporting the X-ray therapy requirements of healthcare providers around the world, from in...

Celltrion Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EMA approval for Inflectr...

TCA Cellular Therapy, LLC

Under the scientific guidance of cellular biologist, Jose J. Minguell, Ph.D., TCA Cellular Therapy, LLC is a biotherapeutic adult stem cell research and development company. The company has been recognized by the FDA as one of the top 10 U.S. companies researching stem cell therapies. Founded in 2006, the privately-held company is located in Covington, Lou...

STEMCELL Technologies Inc

STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. We offer high quality cell culture media, cell separation technologies, instruments, accessory products, and educational resources that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellu...

Cancer Vaccines Ltd

Cancer Vaccines Ltd is a biopharmaceutical company focused on the development and commercialisation of safe and effective therapeutic vaccines for the treatment of cancer. The company was founded in 1999 and won a DTI SMART Award.The attraction of a vaccination based approach to treating cancer is widely acknowledged, and many researchers and clinicians have worked in this area. Historically the a...


More From BioPortfolio on "Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks